Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 7/20 | 0.37 |
| ▸ | PDE4A | P27815 | 6/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.35 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.35 |
| ▸ | PDE5A | O76074 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17814294 | 1.00 | PDE10A (0.43) | PDE10ANPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL18557023 | 1.00 | PDE10A (0.43) | PDE10ANPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL21573348 | 1.00 | PDE10A (0.43) | PDE10ANPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL18520714 | 1.00 | PDE10A (0.43) | PDE10ANPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL18520713 | 1.00 | PDE10A (0.43) | PDE10ANPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL18520712 | 1.00 | PDE10A (0.43) | PDE10ANPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL16388486 | 1.00 | PDE10A (0.43) | PDE10ANPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL17486092 | 0.95 | PDE10A (0.43) | PDE10ANPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL22041445 | 0.95 | PDE10A (0.43) | PDE10ANPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL19679967 | 0.95 | PDE10A (0.43) | PDE10ANPC1RAB9ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250078-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC (US) | 2023-08-10 | — | — | US | disclosed |
| EP-3984997-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | Les Laboratoires Servier SAS (FR) | 2022-04-20 | — | — | EP | disclosed |
| EP-3019484-B1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | LES LABORATOIRES SERVIER SAS (FR) | 2021-09-08 | — | — | EP | disclosed |
| US-10946023-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| EP-3686190-A1 | SYNTHESIS OF THERAPEUTICALLY ACTIVE COMPOUNDS | Agios Pharmaceuticals, Inc. (US) | 2020-07-29 | — | — | EP | disclosed |
| EP-3019490-B1 | N,6-BIS(ARYL OR HETEROARYL)-1,3,5-TRIAZINE-2,4-DIAMINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER | AGIOS PHARMACEUTICALS INC (US) | 2020-06-03 | — | — | EP | disclosed |
| EP-3019483-B1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS INC (US) | 2019-11-20 | — | — | EP | disclosed |
| US-20190117661-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2019-04-25 | — | — | US | disclosed |
| US-10172864-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-10028961-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-10017495-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| EP-2800743-B1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS INC (US) | 2018-04-04 | — | — | EP | disclosed |
| US-9732062-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9724350-B2 | N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as IDH2 mutants inhibitors for the treatment of cancer | AGIOS PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20170107194-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2017-04-20 | — | — | US | disclosed |
| US-9579324-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC (US) | 2017-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190117661-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | PDE10A 2875/4885NPC1 513/4885RAB9A 1818/4885 |
| US-10017495-B2 | Therapeutically active compounds and their methods of use | MCL1, TP53, BRDT | PDE10A 2875/4885NPC1 513/4885RAB9A 1818/4885 |
| US-20230250078-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | PDE10A 2875/4885NPC1 513/4885RAB9A 1818/4885 |
| US-10028961-B2 | Therapeutically active compounds and their methods of use | MCL1, TP53, BRDT | PDE10A 2875/4885NPC1 513/4885RAB9A 1818/4885 |
| US-10172864-B2 | Therapeutically active compounds and their methods of use | MCL1, TP53, BRDT | PDE10A 2875/4885NPC1 513/4885RAB9A 1818/4885 |
| US-10946023-B2 | Therapeutically active compounds and their methods of use | MCL1, TP53, BRDT | PDE10A 2875/4885NPC1 513/4885RAB9A 1818/4885 |
| US-20170107194-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | PDE10A 2875/4885NPC1 513/4885RAB9A 1818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.